296 related articles for article (PubMed ID: 15075331)
1. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
2. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
[TBL] [Abstract][Full Text] [Related]
3. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
[TBL] [Abstract][Full Text] [Related]
4. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.
Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG
J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
7. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Garrett TP; Burgess AW; Gan HK; Luwor RB; Cartwright G; Walker F; Orchard SG; Clayton AH; Nice EC; Rothacker J; Catimel B; Cavenee WK; Old LJ; Stockert E; Ritter G; Adams TE; Hoyne PA; Wittrup D; Chao G; Cochran JR; Luo C; Lou M; Huyton T; Xu Y; Fairlie WD; Yao S; Scott AM; Johns TG
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5082-7. PubMed ID: 19289842
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of Ch806 mimotopes.
Yang L; Jiang H; Shi B; Wang H; Li J; Wang H; Yao M; Li Z
Cancer Immunol Immunother; 2010 Oct; 59(10):1481-7. PubMed ID: 20544195
[TBL] [Abstract][Full Text] [Related]
9. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.
Gan HK; Walker F; Burgess AW; Rigopoulos A; Scott AM; Johns TG
J Biol Chem; 2007 Feb; 282(5):2840-50. PubMed ID: 17092939
[TBL] [Abstract][Full Text] [Related]
10. CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.
Walker F; Orchard SG; Jorissen RN; Hall NE; Zhang HH; Hoyne PA; Adams TE; Johns TG; Ward C; Garrett TP; Zhu HJ; Nerrie M; Scott AM; Nice EC; Burgess AW
J Biol Chem; 2004 May; 279(21):22387-98. PubMed ID: 15016810
[TBL] [Abstract][Full Text] [Related]
11. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
12. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
[TBL] [Abstract][Full Text] [Related]
13. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
